Kenvue (KVUE) Expected to Announce Quarterly Earnings on Thursday

Kenvue (NYSE:KVUE) is expected to be announcing its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.26 per share and revenue of $3.79 billion for the quarter. Kenvue has set its FY 2024 guidance at 1.100-1.200 EPS and its FY24 guidance at $1.10-1.20 EPS.Investors that wish to register for the company’s conference call can do so using this link.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the business posted $0.31 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Performance

Shares of KVUE opened at $21.35 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $40.92 billion, a PE ratio of 38.81, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The business’s fifty day moving average price is $22.05 and its 200 day moving average price is $21.85.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.84%. The ex-dividend date is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on KVUE shares. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Bank of America lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Finally, UBS Group cut their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.